Key clinical point: Eptinezumab showed efficacy for migraine headache prevention in a pair of dose-ranging studies.
Major finding: A 300-mg dosage cut average monthly migraine days by 8.2 /month from baseline, compared with 5.6/month with placebo.
Study details: PROMISE-1 and PROMISE-2, multicenter, randomized studies with a total of 1,741 patients.
Disclosures: PROMISE-1 and PROMISE-2 were sponsored by Alder BioPharmaceuticals, the company developing eptinezumab. Dr. Mechtler has been a speaker on behalf of Allergan, Amgen/Novartis, Boston Biomedical, Promius, Avanir, and Teva, and he has received research funding from Allergan, Autonomic Technologies, Boston Biomedical, and Teva.
Mechtler LL et al. Headache. 2019 Jun;59[S1]:34, Abstract P12.